Imami Nesrina, Hardy Gareth, Pires Antonio, Burton Catherine, Pido-Lopez Jeffrey, Mela Christopher, Gotch Frances
Department of Immunology, Faculty of Medicine, Imperial College of Science, Technology and Medicine, Chelsea and Westminster Hospital, London, UK.
Curr Opin Investig Drugs. 2002 Aug;3(8):1138-45.
HIV-1-specific CD8 cytotoxic and CD4 helper T-lymphocytes, which are respectively the central effector and regulatory cells in viral infections, together with fully functional antigen-presenting cells, are essential at all stages of HIV-1 infection to control viral activity. Recent studies indicate that such protective HIV-1-specific immune responses can be preserved/induced in HIV-1-infected individuals, utilizing strategies such as treatment interruption after early HAART. Despite successful combination antiretroviral drug therapy, strong anti-HIV-1 T-cell responses are often not apparent in chronic HIV-1 infection, diminishing the probability of viral eradication. Thus, the therapeutic use of immunization and cytokines are required to induce and steer immunity towards a desirable outcome. Here, we review and discuss therapeutic immunization and immunotherapy with regard to their potential use in the treatment of chronic HIV-1 infection.
HIV-1特异性CD8细胞毒性T淋巴细胞和CD4辅助性T淋巴细胞分别是病毒感染中的核心效应细胞和调节细胞,它们与功能完备的抗原呈递细胞一起,在HIV-1感染的各个阶段对于控制病毒活性至关重要。最近的研究表明,利用诸如早期高效抗逆转录病毒治疗(HAART)后中断治疗等策略,在HIV-1感染个体中可以保留/诱导出这种具有保护性的HIV-1特异性免疫反应。尽管联合抗逆转录病毒药物治疗取得了成功,但在慢性HIV-1感染中,强烈的抗HIV-1 T细胞反应往往并不明显,这降低了病毒根除的可能性。因此,需要通过免疫接种和细胞因子的治疗性应用来诱导并引导免疫反应朝着理想的结果发展。在此,我们就治疗性免疫接种和免疫疗法在慢性HIV-1感染治疗中的潜在应用进行综述和讨论。